Light-Activated ointment shows promise for rare skin cancer
NCT ID NCT05872854
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 29 times
Summary
This study tested a synthetic ointment called hypericin (HyBryte) combined with visible light to treat mycosis fungoides, a rare type of skin lymphoma. Ten adults with early-stage disease applied the ointment and received light treatments every 6 weeks for up to 54 weeks. The goal was to see if the treatment could reduce the severity of skin lesions, measured by redness, scaling, thickness, and size.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, 19034, United States
Conditions
Explore the condition pages connected to this study.